Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences
21 Ottobre 2024 - 1:01PM
Business Wire
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage
gene editing company utilizing its novel proprietary ARCUS®
platform to develop in vivo gene editing therapies for
sophisticated gene edits, today announced that it will participate
in the following upcoming investor conferences.
Longwood Boston CEO Conference Date: Monday, October 28,
2024 Time: 11:10 AM ET Title: Expanding Platform Potential Format:
Panel
Guggenheim Inaugural Healthcare Conference Date: Monday,
November 11, 2024 Time: 3:00 PM ET Location: InterContinental
Boston Format: Fireside Chat Webcast Link: Register Here
A live webcast for the Guggenheim Inaugural Healthcare
Conference will also be accessible on Precision’s website in the
Investors section under Events & Presentations at
investor.precisionbiosciences.com. An archived replay of the
webcasts will be available for approximately 30 days following the
event.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage gene editing
company dedicated to improving life (DTIL) with its novel and
proprietary ARCUS® genome editing platform that differs from other
technologies in the way it cuts, its smaller size, and its simpler
structure. Key capabilities and differentiating characteristics may
enable ARCUS nucleases to drive more intended, defined therapeutic
outcomes. Using ARCUS, the Company’s pipeline is comprised of in
vivo gene editing candidates designed to deliver lasting cures for
the broadest range of genetic and infectious diseases where no
adequate treatments exist. For more information about Precision
BioSciences, please visit www.precisionbiosciences.com.
The ARCUS® platform is being used to develop in vivo gene
editing therapies for sophisticated gene edits, including gene
insertion (inserting DNA into gene to cause expression/add
function), elimination (removing a genome e.g. viral DNA or mutant
mitochondrial DNA), and excision (removing a large portion of a
defective gene by delivering two ARCUS nucleases in a single
AAV).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241021549147/en/
Investor and Media Contact: Naresh Tanna Vice President
of Investor Relations naresh.tanna@precisionbiosciences.com
Grafico Azioni Precision BioSciences (NASDAQ:DTIL)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Precision BioSciences (NASDAQ:DTIL)
Storico
Da Gen 2024 a Gen 2025
